Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study (HERS)

Circulation

Volumn 105, Issue 25, 2002, Pages 2962-2967

  Herrington, David M ^a   Vittinghoff, Eric ^a   Lin, Feng ^a   Fong, Josephine ^a   Harris, Fran ^a   Hunninghake, Donald ^a   Bittner, Vera ^a   Schrott, Helmut G ^a   Blumenthal, Roger S ^a   Levy, Robert ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary disease; Hormones; Lipids; Risk factors; Women

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; FLUINDOSTATIN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENOPAUSE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

AGED; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DRUG INTERACTIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDROXYPROGESTERONE 17-ACETATE; MYOCARDIAL INFARCTION; POSTMENOPAUSE; THROMBOEMBOLISM;

EID: 0037173078     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000019406.74017.B2     Document Type: Article

References (27)

1. Cardiovascular disease in women: A statement for healthcare professionals from the American Heart Association
2. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) trial
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
5. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women
6. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease
7. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flowmediated vasodilation in postmenopausal women with coronary artery disease
8. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia
9. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Asymptomatic Carotid Artery Progression Study
10. Long-term effects of pravastatin on plasma concentration of C-reactive protein
11. The Heart and Estrogen/progestin Replacement Study: Design, methods and baseline characteristics
12. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
13. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
14. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/progestin Replacement Study (HERS)
15. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S)
16. Carcinogenicity of lipid-lowering drugs
17. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
18. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study
19. Use of statins and the subsequent development of deep vein thrombosis
20. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
21. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) study
22. Hormone replacement therapy, inflammation, and hemostasis in elderly women
23. Hormone replacement therapy and increased plasma concentration of C-reactive protein
24. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
25. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women
26. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women
27. Regression of atherosclerosis in female monkeys